RaySearch enters into distribution agreement with Hitachi

4 November 2013 – RaySearch Laboratories AB has entered into a long-term distribution agreement with Hitachi Medical Corporation (Hitachi) based in Tokyo, Japan. The agreement means that Hitachi will be fully responsible for marketing, sales and service of RaySearch’s proprietary treatment planning system RayStation® on the Japanese market from April 1, 2014.

Japan is one of the largest radiation therapy markets in the world with approximately 700 radiation therapy clinics. Hitachi is a leading distributor of radiation therapy equipment in Japan and represents a wide range of international radiation therapy equipment suppliers. The company was founded in 1949 and has over 5,000 employees globally. Hitachi is highly experienced in the field of radiation therapy treatment planning systems serving 300 Japanese radiation therapy centers with a dedicated sales and support unit with over 30 employees. In addition Hitachi has a broad network of local sales and service staff covering all of Japan.

“Hitachi Medical Corporation is a leading distributor of advanced radiation therapy equipment with a long track record and a large installed base, so we are of course delighted that they have elected to partner with RaySearch. We will now work closely together with Hitachi’s experienced experts to satisfy the needs of the Japanese clinics and I am fully convinced that this collaboration will be highly fruitful for both companies”, says Johan Löf, CEO of RaySearch.”

About RayStation®
RayStation® integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian, Accuray and Brainlab. To date, 15 products have been launched through partners and RaySearch’s software is used at over 2,300 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.
©

Acceptance Test Results of ProTom International Proton Therapy Technology Exceeds Expectations

Acceptance Test Results of ProTom International Proton Therapy Technology Exceeds Expectations

FLINT, Mich.

Initial acceptance test results of ProTom International, Inc.'s (“ProTom”) Radiance 330® Proton Therapy System (“Radiance 330”) are exceeding the expectations of medical physicists charged with clinical commissioning at the McLaren Proton Therapy Center (“MPTC”) in Flint, Michigan.

Speaking of the depth-dose data acquired from the scanning proton beam system during acceptance testing, McLaren's principal consulting physicist Alfred R. Smith, Ph.D. stated, “The raw data is extremely clean and smooth.” Depth-dose profiles characterize the key quality of protons – the Bragg peak – a physical property of charged-particle beams causing the vast majority of proton energy to be delivered over a short and precisely-defined range, confining the high dose to the target volume and sparing normal tissues in close proximity.

The Radiance 330® employs the Proton Beam Scanning (PBS) treatment delivery technique, and the McLaren team tested key characteristics of the scanned beam delivered to instrumentation in water phantoms. “We have been impressed by the stability of the system during our testing,” said Sung Park, Ph.D., Chief Physicist for the MPTC. “The spot size and spot profiles are well-described by a Gaussian distribution and demonstrate excellent radial symmetry. This bodes well for the dosimetry we can expect from ProTom's system.”

Dr. Park continued, “We observed very impressive beam performance during ProTom’s technical commissioning, and these results are now being independently measured and reproduced by our clinical physics team. We have collected all the data necessary to validate our treatment planning system for Radiance 330. Beam modeling is underway; next, we’ll deliver some sample plans to phantom for comparison. We look forward to clinically commissioning our first patient treatment room.”

(Photos: Business Wire)

About ProTom International, Inc.
ProTom is a medical device company committed to offering the most advanced and affordable generation of proton therapy systems so that patients in need of this cutting-edge treatment may have this option close to home, close to their physicians. ProTom continues to accelerate innovation so physicians and the patients they care for can have the very best weapons in the fight against cancer. To find out more about the future of proton therapy, visit us at www.protominternational.com.

About McLaren Health Care
McLaren Health Care Corporation, headquartered in Flint, MI, is a fully integrated health network, committed to quality, evidence-based patient care and cost efficiency. The McLaren system includes 11 hospitals, ambulatory surgery centers, imaging centers, the state’s only proton therapy center, an employed primary care physician network, commercial and Medicaid HMOs covering over 250,000 lives, home health care and hospice, durable medical equipment, retail pharmacy services, and a wholly-owned medical malpractice insurance company. McLaren operates the state’s largest network of cancer centers and providers anchored by Karmanos Cancer Institute - one of only two NCI-designated cancer centers in the state. McLaren has 19,500 employees and more than 20,000 network physicians. The operations and services of MHC are housed in over 300 facilities serving a 53-county market with a population in excess of 6.5 million lives. Learn more at www.mclaren.org.

The Radiance 330® Proton Therapy System has not been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution in the U.S. at this time.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20131105006183/en/

Contact:
ProTom International
Stephen Sledge, 904-502-4032
ssledge@protominternational.com
or
McLaren Health Care
Kevin Tompkins, 810-342-1173
KevinTo@mclaren.org
©